secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K/A
Filed at:   2023-03-10T23:59:59+00:00
Accession:  0001193125-23-066791
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine reports Q4 net loss $39.3M, FY2022 net loss $121.8M; nominates PM359 for CGD
--------------------------------------------------------------------------------

- Q4 2022 net loss $39.3M improved from $62.9M in Q4 2021; FY2022 net loss $121.8M vs $165.4M prior year.
- R&D expenses $29.1M in Q4 and $86.7M for FY2022; G&A $9.6M and $29.8M, respectively.
- Cash, short-term investments $293.9M as of Dec 31, 2022, up from $269.6M year-end 2021, boosted by $180.2M IPO net proceeds.
- Nominated PM359 as first development candidate for chronic granulomatous disease (CGD); IND-enabling studies planned for 2023.
- Preclinical proof-of-concept data for FRDA, CF, and Wilson's disease; first IND filing expected as early as 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/0001193125-23-066791-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000119312523066791/d342589d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-066791

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer